Protalix BioTherapeutics, Inc. 8-K

What Happened

• Protalix BioTherapeutics (PLX) and partner Chiesi Global Rare Diseases announced that the European Commission (EC) approved a new dosing regimen — 2 mg/kg every 4 weeks (E4W) — for Elfabrio® (pegunigalsidase alfa). The decision was announced in a press release dated March 9, 2026 and follows a positive opinion from the EMA’s CHMP.
• The approval covers adults living with Fabry disease who are stable on enzyme replacement therapy (ERT).

Key Details

• EC approval: 2 mg/kg every 4 weeks (E4W) dosing regimen for Elfabrio (pegunigalsidase alfa).
• Indication scope: adults with Fabry disease who are stable with an existing ERT.
• Regulatory timeline: CHMP gave a positive opinion prior to the EC decision; press release dated March 9, 2026.
• Partner: announcement made jointly with Chiesi Global Rare Diseases (unit of Chiesi Farmaceutici S.p.A.).

Why It Matters

• This regulatory approval expands the labeled dosing options for Elfabrio in the EU, which can affect how clinicians prescribe the therapy for patients switching or continuing ERT.
• For investors, the decision may improve market access and commercial potential for Elfabrio in Europe when used under the approved conditions, though the filing does not include financial guidance or projected revenue impacts.
• The announcement underscores the ongoing collaboration with Chiesi on development and commercialization in the rare-disease space.